Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ultragenyx Pharmaceutical Inc.

www.ultragenyx.com

Latest From Ultragenyx Pharmaceutical Inc.

Asia Deal Watch: Daiichi Sankyo Pays $200m To Ultragenyx For AAV Technology Access

A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context

Deals Business Strategies

Palforzia Peanut Allergy Immunotherapy: Aimmune CEO On REMS Restrictions, Manufacturing

Aimmune CEO Jayson Dallas tells the Pink Sheet how physicians and patients are being certified to use Palforzia and how the product's food-based manufacturing process is actually an advantage. 

Safety Manufacturing

US FDA's Stein To Sponsors: New Leadership From OND Reorganization Won't Change Your Development Plans

Office of New Drugs Director Peter Stein told sponsors during a panel discussion that they will be able to continue agreed upon development programs despite leadership changes arising from the OND reorganization; industry speakers excited, but also have some reservations, about the new OND.

Leadership FDA

Individual Endpoints Pose Challenge For US FDA In Review Of Rare Disease Drug

FDA reviewer describes difficulties in reviewing application for Mepsevii for Sly syndrome; the experience provides perspective for other companies seeking to use novel endpoints.

Drug Review FDA
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ultragenyx Pharmaceutical LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ultragenyx Pharmaceutical Inc.
  • Senior Management
  • Emil Kakkis, MD, PhD, Pres. & CEO
    Shalini Sharp, EVP, CFO
    Thomas Kassberg, EVP, CBO
    Camille L Bedrosian, MD, EVP, CMO
    Erik Harris, EVP, Chief Commercial Officer
  • Contact Info
  • Ultragenyx Pharmaceutical Inc.
    Phone: (415) 483-8800
    60 Leveroni Ct.
    Novato, CA 94949
    USA
UsernamePublicRestriction

Register